跳至主要内容
临床试验/NCT06875362
NCT06875362已完成不适用

Safety and Efficacy of LR08 in Modulating Gut Microbiota and Improving Metabolic Health in Healthy Adults: A Clinical Study

Wecare Probiotics Co., Ltd.1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2025年3月10日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
1
主要终点
Changes in Immune Function

研究概览

简要总结

Evaluate the efficacy and safety of LR08 as a dietary supplement compared to a placebo in enhancing intestinal health and immune function in healthy adults.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Willing to attend 3 follow-up visits during the intervention period
  • Agree to provide blood, urine, and stool samples twice during the intervention period
  • Good eyesight, able to read and write, and capable of wearing glasses if needed
  • Good hearing and able to fully comprehend all instructions during the intervention

排除标准

  • Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)
  • History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)
  • History of or currently receiving treatment for mental health disorders such as alcohol/drug/substance abuse, schizophrenia, psychosis, or bipolar disorder
  • Currently taking medication for depression or low mood
  • Presence of internal organ failure (e.g., heart, liver, or kidney failure)
  • History of radiation therapy or chemotherapy treatments
  • Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period
  • History of hepatitis (B or C), HIV, or syphilis

结局指标

主要结局

Changes in Immune Function

时间窗: Week 0 and Week 8

Evaluation of immune function markers, specifically immunoglobulin A (IgA) concentration, to assess the effects of LR08 supplementation compared to placebo.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验